OSL.AU · OncoSil Medical Limited

-

Please sign in to comment on OSL.AU

1 Comment

Admin

4 years, 1 month ago

OncoSil Medical Limited is currently in a long term downtrend where the price is trading 42.9% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

OncoSil Medical Limited's total revenue sank by 32.3% to $829K since the same quarter in the previous year.

Its net income has dropped by 39.5% to $-5M since the same quarter in the previous year.

Finally, its free cash flow fell by 220.9% to $-2M since the same quarter in the previous year.

Based on the above factors, OncoSil Medical Limited gets an overall score of 1/5.

Sector	Healthcare
Industry	Medical Devices
ISIN	AU000000OSL3
CurrencyCode	AUD
Exchange	AU

Beta	1.15
Market Cap	14M
PE Ratio	None
Target Price	0.06
Dividend Yield	None

ABOUT

OncoSil Medical Limited

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

OSL.AU · OncoSil Medical Limited

-

OncoSil Medical Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest OncoSil Medical Limited using a moving average strategy